Gene therapy for primary immunodeficiencies

Human Gene Therapy

Volumn 23, Issue 7, 2012, Pages 668-675

  Rivat, Christine ^a,b   Santilli, Giorgia ^a   Gaspar, H Bobby ^a,b   Thrasher, Adrian J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BUSULFAN; FLUDARABINE; MELPHALAN; RAG1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETROVIRUS VECTOR; RITUXIMAB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL (TOPIC); EX VIVO GENE TRANSFER; FRANCE; GENE MUTATION; GENE THERAPY; GERMANY; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HOMOLOGOUS RECOMBINATION; HUMAN; ITALY; JAK3 DEFICIENCY; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; NONHUMAN; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; UNITED KINGDOM; UNITED STATES; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; CLINICAL TRIALS AS TOPIC; GAMMARETROVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HOMOLOGOUS RECOMBINATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES;

EID: 84864358304     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.116     Document Type: Review

References (53)

1. Aiuti, A., Slavin, S., Aker, M., et al. (2002). Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413. (Pubitemid 34734219)
2. Aiuti, A., Cassani, B., Andolfi, G., et al. (2007). Multilineage hematopoietic reconstitution without clonal selection in ADASCID patients treated with stem cell gene therapy. J. Clin. Invest. 117, 2233-2240. (Pubitemid 47219568)
3. Aiuti, A., Cattaneo, F., Galimberti, S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447-458.
4. Avedillo Diez, I., Zychlinski, D., Coci, E.G., et al. (2011). Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol. Pharm. 8, 1525-1537.
5. Bauer, T.R., Jr., Hickstein, D.D., (2000). Gene therapy for leukocyte adhesion deficiency. Curr. Opin. Mol. Ther. 2, 383-388. (Pubitemid 30662866)
6. Benjelloun, F., Garrigue, A., Demerens-de Chappedelaine, C., et al. (2008). Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol. Ther. 16, 1490-1499.
7. Bianchi, M., Hakkim, A., BriNKmann, V., et al. (2009). Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 114, 2619-2622.
8. BoNKobara, M., Zukas, P.K., Shikano, S., Nakamura, S., et al. (2001). Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter. J. Immunol. 167, 6893-6900. (Pubitemid 33144182)
9. Bordignon, C., Notarangelo, L.D., Nobili, N., et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270, 470-475.
10. Boztug, K., Dewey, R.A., and Klein, C. (2006). Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr. Opin. Mol. Ther. 8, 390-395. (Pubitemid 44566780)
11. Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
12. Brown, M.P., Topham, D.J., Sangster, M.Y., et al. (1998). Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat. Med. 4, 1253-1260. (Pubitemid 28512105)
13. Cattoglio, C., Pellin, D., Rizzi, E., et al. (2010). High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 116, 5507-5517.
14. Chan, B., Wara, D., Bastian, J., et al. (2005). Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin. Immunol. 117, 133-143. (Pubitemid 41407723)
15. Charrier, S., Stockholm, D., Seye, K., et al. (2005). A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther. 12, 597-606. (Pubitemid 40468107)
16. Charrier, S., Dupre, L., Scaramuzza, S., et al. (2007). Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 14, 415-428.
17. Chinen, J., Davis, J., De Ravin, S.S., et al. (2007). Gene therapy improves immune function in preadolescents with X-liNKed severe combined immunodeficiency. Blood 110, 67-73. (Pubitemid 47026820)
18. Cooray, S., Howe, S.J., and Thrasher, A.J. (2012). Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol. 507, 29-57.
19. Deichmann, A., Brugman, M.H., Bartholomae, C.C., et al. (2011). Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol. Ther. 19, 2031-2039.
20. Gaspar, H.B., Cooray, S., Gilmour, K.C., et al. 2011a. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-liNKed severe combined immunodeficiency. Sci. Transl. Med. 3, 97ra79.
21. Gaspar, H.B., Cooray, S., Gilmour, K.C., et al. 2011b. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80.
22. Gentner, B., Visigalli, I., Hiramatsu, H., et al. (2010). Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci. Transl. Med. 2, 58ra84.
23. Grez, M., Reichenbach, J., Schwable, J., et al., (2011). Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol. Ther. 19, 28-35.
24. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
25. Hacein-Bey-Abina, S., Hauer, J., Lim, A., et al. (2010). Efficacy of gene therapy for X-liNKed severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364.
26. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
27. Hunter, M.J., Tuschong, L.M., Fowler, C.J., et al. (2011). Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression. Mol. Ther. 19, 113-121.
28. Kang, E.M., Choi, U., Theobald, N., et al. (2010). Retrovirus gene therapy for X-liNKed chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115, 783-791.
29. Kang, H.J., Bartholomae, C.C., Paruzynski, A., et al. (2011). Retroviral gene therapy for X-liNKed chronic granulomatous disease: results from phase I/II trial. Mol. Ther. 19, 2092-2101.
30. Kerns, H.M., Ryu, B.Y., Stirling, B.V., et al. (2010). B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-liNKed agammaglobulinemia. Blood 115, 2146-2155.
31. Lois, C., Hong, E.J., Pease, S., et al. (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868-872. (Pubitemid 34118370)
32. Lombardo, A., Genovese, P., Beausejour, C.M., et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25, 1298-1306. (Pubitemid 350076515)
33. Malech, H.L., Maples, P.B., Whiting-Theobald, N., et al. (1997). Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. U. S. A. 94, 12133-12138. (Pubitemid 27467855)
34. Marodon, G., Mouly, E., Blair, E.J., et al. (2003). Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 101, 3416-3423. (Pubitemid 36857923)
35. McCauslin, C.S., Wine, J., Cheng, L., et al. (2003). In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals. Blood 102, 843-848. (Pubitemid 36917774)
36. Montiel-Equihua, C.A., Zhang, L., Knight, S., et al. (2012). The beta-globin locus control region in combination with the EF1alpha short promoter allows enhanced lentiviral vectormediated erythroid gene expression with conserved multilineage activity. Mol. Ther. doi: 10.1038/mt.2012.50.
37. Moreau, T., Bardin, F., Imbert, J., et al. (2004). Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol. Ther. 10, 45-56. (Pubitemid 38878148)
38. Munoz, I.G., Prieto, J., Subramanian, S., et al. (2011). Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. Nucleic Acids Res. 39, 729-743.
39. Noguchi, M., Yi, H., Rosenblatt, H.M., et al. (1993). Interleukin-2 receptor gamma chain mutation results in X-liNKed severe combined immunodeficiency in humans. Cell 73, 147-157. (Pubitemid 23115456)
40. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-liNKed chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
41. Pai, S.Y., Notarangelo, L.D., Harris, C., et al. (2011). Somatic gene therapy for X-liNKed severe combined immunodeficiency using a self-inactivating modified gammaretroviral vector results in an improved preclinical safety profile and early clinical efficacy in a human patient. Blood 118: 164.
42. Pike-Overzet, K., Rodijk, M., Ng, Y.Y., et al. (2011). Correction of murine Rag1 deficiency by self-inactivating lentiviral vectormediated gene transfer. Leukemia 25, 1471-1483.
43. Sacco, M.G., Ungari, M., Cato, E.M., et al. (2000). Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome. Cancer Gene Ther. 7, 1299-1306.
44. Santilli, G., Almarza, E., Brendel, C., et al. (2011). Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol. Ther. 19, 122-132.
45. Scaramuzza, S., Biasco, L., Ripamonti, A., et al. (2012). Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther. doi: 10.1038/mt.2012.23.
46. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204.
47. Tahara, M., Pergolizzi, R.G., Kobayashi, H., et al. (2004). Transsplicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-liNKed immunodeficiency. Nat. Med. 10, 835-841. (Pubitemid 39070857)
48. Thrasher, A.J., Hacein-Bey-Abina, S., Gaspar, H.B., et al. (2005). Failure of SCID-X1 gene therapy in older patients. Blood 105, 4255-4257. (Pubitemid 40720770)
49. Throm, R.E., Ouma, A.A., Zhou, S., et al. (2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113, 5104-5110.
50. Van Til, N.P., De Boer, H., Mashamba, N., et al. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol. Ther. doi: 10.1038/mt.2012.110.
51. Yates, F., Malassis-Seris, M., Stockholm, D., et al. (2002). Gene therapy of RAG-2-/-mice: sustained correction of the immunodeficiency. Blood 100, 3942-3949. (Pubitemid 35396859)
52. Yu, P.W., Tabuchi, R.S., Kato, R.M., et al. (2004). Sustained correction of B-cell development and function in a murine model of X-liNKed agammaglobulinemia (XLA) using retroviralmediated gene transfer. Blood 104, 1281-1290. (Pubitemid 39166501)
53. Zhang, F., Frost, A.R., Blundell, M.P., et al. (2010). A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol. Ther. 18, 1640-1649.